YS Biopharma Co., Ltd. Holds Successful Extraordinary General Meeting in Hong Kong

YS Biopharma Co., Ltd., a prominent biopharmaceutical company traded on Nasdaq as YS, recently conducted an extraordinary general meeting in Hong Kong on May 21, 2024. The meeting saw the approval of significant resolutions, including alterations to the company's name and the appointment of new directors.

The company is currently in the process of updating its records with the Registrar of Companies in the Cayman Islands to reflect these changes. Furthermore, YS Biopharma is working closely with the Nasdaq Stock Market LLC to update the trading symbols for its ordinary shares and warrants.

Specializing in the development and production of innovative vaccines and therapeutic biologics for infectious diseases and cancer, YS Biopharma leverages its proprietary PIKA® immunomodulating technology platform. The company's primary focus lies in creating advanced preventive and therapeutic solutions for diseases like Rabies, Coronavirus, Hepatitis B, Influenza, and Shingles.

With a global presence in China, the United States, Singapore, and the Philippines, YS Biopharma is led by a management team with extensive experience in the biopharmaceutical sector. For further details about the company and its endeavors, please visit the investor relations website.

YS Biopharma Co., Ltd.'s recent extraordinary general meeting in Hong Kong marked a pivotal moment for the company, with key resolutions being approved and changes set in motion. As a leading player in the biopharmaceutical industry, YS Biopharma continues to drive innovation in vaccine and therapeutic development, aiming to combat infectious diseases and cancer effectively. With its global operations and experienced management team, the company remains dedicated to advancing healthcare solutions for a better tomorrow.